Polyvalency (chemistry)
In chemistry, polyvalency (or polyvalence, multivalency) is the property of molecules and larger species, such as antibodies, medical drugs, and even nanoparticles surface-functionalized with ligands, like spherical nucleic acids, that exhibit more than one supramolecular interaction.[1][2][3] For the number of chemical bonds of atoms, the term "valence" is used (Fig. 1). For both atoms and larger species, the number of bonds may be specified: divalent species can form two bonds; a trivalent species can form three bonds; and so on.[4]
Species that have polyvalency usually show enhanced or cooperative binding compared to their monovalent counterparts.[5][6][7][8] Nanoparticles with multiple nucleic acid strands on their surfaces (e.g., DNA) can form multiple bonds with one another by DNA hybridization to form hierarchical assemblies, some of which are highly crystalline in nature.[9]
References
[edit]- ^ Vance, David; Shah, Mrinal; Joshi, Amit; Kane, Ravi S. (15 October 2008). "Polyvalency: a promising strategy for drug design". Biotechnology and Bioengineering. 101 (3): 429–434. doi:10.1002/bit.22056. PMID 18727104.
- ^ Wu, Albert M.; Wu, June H.; Liu, Jia-Hau; Singh, Tanuja; André, Sabine; Kaltner, Herbert; Gabius, Hans-Joachim (April 2004). "Effects of polyvalency of glycotopes and natural modifications of human blood group ABH/Lewis sugars at the Galbeta1-terminated core saccharides on the binding of domain-I of recombinant tandem-repeat-type galectin-4 from rat gastrointestinal tract (G4-N)". Biochimie. 86 (4–5): 317–326. doi:10.1016/j.biochi.2004.03.007. PMID 15194236.
- ^ Kane, Ravi (2006-11-01). "Polyvalency: Recent developments and new opportunities for chemical engineers". AIChE Journal. 52 (11): 3638–3644. Bibcode:2006AIChE..52.3638K. doi:10.1002/aic.11011. Retrieved 2020-08-04.
- ^ Cartmell, E.; Fowles, G. W. A. (1983). Valency and Molecular Structure (4th ed.). ISBN 0-408-70809-3.
- ^ Crothers, D.; Metzger, H. (1972). “The influence of polyvalency on the binding properties of antibodies”. Immunochemistry. 9 (3): 341–57. doi: 10.1016/0019-2791(72)90097-3
- ^ Davis, K. A.; et al. (1999). “Determination of CD4 antigen density on cells: Role of antibody valency, avidity, clones, and conjugation”. Cytometry Part A. 33 (2):197–205. doi: 10.1002/(SICI)1097-0320(19981001)33:2<197::AID-CYTO14>3.0.CO;2-P
- ^ Jones, M. A.; et al. (2015) “Programmable materials and the nature of the DNA bond”. Science. 347 (6224): 840. doi: 10.1126/science.1260901
- ^ Hu, X.; et al. (2019) “Valency-Controlled Molecular Spherical Nucleic Acids with Tunable Biosensing Performances”. Anal. Chem. 91 (17): 11374–11379. doi: 10.1021/acs.analchem.9b02614
- ^ Macfarlane, R. J.; et al. (2011). "Nanoparticle Superlattice Engineering with DNA". Science. 334 (6053): 204–08. doi:10.1126/science.1210493.